RU2004139090A - Способы применения соединений, подобных артемизинину, для профилактики или задержки возникновения злокачественных опухолей - Google Patents
Способы применения соединений, подобных артемизинину, для профилактики или задержки возникновения злокачественных опухолей Download PDFInfo
- Publication number
- RU2004139090A RU2004139090A RU2004139090/14A RU2004139090A RU2004139090A RU 2004139090 A RU2004139090 A RU 2004139090A RU 2004139090/14 A RU2004139090/14 A RU 2004139090/14A RU 2004139090 A RU2004139090 A RU 2004139090A RU 2004139090 A RU2004139090 A RU 2004139090A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- iron
- artemisinin
- subject
- endoperoxide
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 15
- 229960004191 artemisinin Drugs 0.000 title claims 6
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 title claims 6
- 229930101531 artemisinin Natural products 0.000 title claims 6
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000003211 malignant effect Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 16
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 150000003254 radicals Chemical class 0.000 claims 9
- 229910052742 iron Inorganic materials 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 5
- -1 terpene lactones Chemical class 0.000 claims 4
- 229960000981 artemether Drugs 0.000 claims 3
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 claims 3
- 230000003834 intracellular effect Effects 0.000 claims 3
- UYVWNPAMKCDKRB-UHFFFAOYSA-N 1,2,4,5-tetraoxane Chemical class C1OOCOO1 UYVWNPAMKCDKRB-UHFFFAOYSA-N 0.000 claims 2
- 150000004903 1,2,4-trioxanes Chemical class 0.000 claims 2
- 150000001298 alcohols Chemical class 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 229960002521 artenimol Drugs 0.000 claims 2
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 claims 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 2
- 229930016266 dihydroartemisinin Natural products 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 150000002170 ethers Chemical class 0.000 claims 2
- 230000037041 intracellular level Effects 0.000 claims 2
- 150000003871 sulfonates Chemical class 0.000 claims 2
- 235000007586 terpenes Nutrition 0.000 claims 2
- ZITFTYGHYGPDAV-UHFFFAOYSA-L 2-aminoacetic acid;iron(2+);sulfate Chemical compound [H+].[Fe+2].NCC([O-])=O.[O-]S([O-])(=O)=O ZITFTYGHYGPDAV-UHFFFAOYSA-L 0.000 claims 1
- UQSASSBWRKBREL-UHFFFAOYSA-K 2-hydroxyethyl(trimethyl)azanium;iron(3+);2-oxidopropane-1,2,3-tricarboxylate;trihydrate Chemical compound O.O.O.[Fe+3].C[N+](C)(C)CCO.[O-]C(=O)CC([O-])(C([O-])=O)CC([O-])=O UQSASSBWRKBREL-UHFFFAOYSA-K 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- UVNHKOOJXSALHN-ILQPJIFQSA-N artelinic acid Chemical compound O([C@@H]1[C@H](C)[C@@H]2CC[C@H]([C@@H]3CC[C@]4(C)O[C@H]([C@]23OO4)O1)C)CC1=CC=C(C(O)=O)C=C1 UVNHKOOJXSALHN-ILQPJIFQSA-N 0.000 claims 1
- 229960002970 artemotil Drugs 0.000 claims 1
- NLYNIRQVMRLPIQ-XQLAAWPRSA-N artemotil Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OCC)O[C@H]4[C@]32OO[C@@]1(C)O4 NLYNIRQVMRLPIQ-XQLAAWPRSA-N 0.000 claims 1
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 claims 1
- 229960004991 artesunate Drugs 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229950003601 ferrocholinate Drugs 0.000 claims 1
- 108010045676 holotransferrin Proteins 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 1
- 229940046411 iron,peptonized Drugs 0.000 claims 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- FOWDZVNRQHPXDO-UHFFFAOYSA-N propyl hydrogen carbonate Chemical compound CCCOC(O)=O FOWDZVNRQHPXDO-UHFFFAOYSA-N 0.000 claims 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38692802P | 2002-06-06 | 2002-06-06 | |
| US60/386,928 | 2002-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2004139090A true RU2004139090A (ru) | 2005-06-10 |
Family
ID=29736235
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004139090/14A RU2004139090A (ru) | 2002-06-06 | 2003-06-06 | Способы применения соединений, подобных артемизинину, для профилактики или задержки возникновения злокачественных опухолей |
| RU2004139096/15A RU2325156C2 (ru) | 2002-06-06 | 2003-06-06 | Ковалентные конъюгаты между родственными артемизинину эндопероксидами и железосодержащими белками и способы применения |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2004139096/15A RU2325156C2 (ru) | 2002-06-06 | 2003-06-06 | Ковалентные конъюгаты между родственными артемизинину эндопероксидами и железосодержащими белками и способы применения |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20040058981A1 (enExample) |
| EP (2) | EP1553935A4 (enExample) |
| JP (2) | JP2005529938A (enExample) |
| CN (3) | CN1668293A (enExample) |
| AU (2) | AU2003243418B2 (enExample) |
| BR (2) | BR0311627A (enExample) |
| CA (2) | CA2488347A1 (enExample) |
| NZ (2) | NZ537114A (enExample) |
| RU (2) | RU2004139090A (enExample) |
| WO (1) | WO2003103588A2 (enExample) |
| ZA (1) | ZA200500023B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103393672A (zh) | 2003-02-12 | 2013-11-20 | 乔治敦大学 | 青蒿素在治疗致癌病毒诱导的肿瘤和治疗病毒感染中的应用 |
| US8394365B2 (en) * | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
| KR20120073370A (ko) * | 2003-09-17 | 2012-07-04 | 넥타르 테라퓨틱스 | 다분지형 고분자 전구약물 |
| CN1255106C (zh) * | 2003-09-26 | 2006-05-10 | 李国桥 | 复方青蒿素 |
| US20050096369A1 (en) * | 2003-11-04 | 2005-05-05 | Hoang Ba X. | Compositions and methods for treating cellular proliferation disorders |
| CA2546210A1 (en) * | 2003-11-19 | 2005-06-02 | Vecta Ltd. | Methods and compositions for the treatment of helicobacter pylori-associated diseases using endoperoxide bridge-containing compounds |
| CN1311832C (zh) * | 2005-01-12 | 2007-04-25 | 四川科伦药业股份有限公司 | 溴代二氢青蒿素的医药用途 |
| US20060270863A1 (en) * | 2005-05-27 | 2006-11-30 | Amyris Biotechnologies | Conversion of amorpha-4,11-diene to artemisinin and artemisinin precursors |
| NZ568049A (en) * | 2005-10-20 | 2011-10-28 | Epipharm Gmbh | Treatment and prevention of benign pigmented moles (nevi) using artemisinine and the derivatives thereof |
| US7462627B2 (en) * | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| US7671067B2 (en) * | 2006-02-09 | 2010-03-02 | Enzon Pharmaceuticals, Inc. | Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin |
| US20070231300A1 (en) * | 2006-03-28 | 2007-10-04 | Washington, University Of | Covalent conjugates between endoperoxides and transferrin and lactoferrin receptor-binding agents |
| WO2008046109A2 (en) * | 2006-10-13 | 2008-04-17 | University Of Washington | Conjugates of artemisinin-related endoperoxides and hydrazone derivatives for the treatment of cancer |
| MX2009005780A (es) * | 2006-11-30 | 2009-06-10 | Nektar Therapeutics Al Corp | Metodo para preparar un conjugado de polimeros. |
| KR20090108082A (ko) * | 2007-02-09 | 2009-10-14 | 엔존 파마슈티컬즈, 인코포레이티드 | 7-에틸-10-하이드록시캄토테신 다분지형 고분자 접합체를 이용한 내성 또는 불응성 암의 치료방법 |
| SG172737A1 (en) * | 2008-01-30 | 2011-07-28 | Pieris Ag | Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinaseand methods for obtaining the same |
| CN101323569B (zh) * | 2008-07-24 | 2011-01-26 | 上海交通大学 | 倍半萜青蒿萜酯ae及其提取纯化方法 |
| CN102159250B (zh) | 2008-08-11 | 2014-08-06 | 尼克塔治疗公司 | 多臂的聚合烷酸酯偶联物 |
| TW201010732A (en) * | 2008-08-29 | 2010-03-16 | Enzon Pharmaceuticals Inc | Method of treating RAS associated cancer |
| RS59607B1 (sr) | 2008-09-23 | 2020-01-31 | Nektar Therapeutics | Metod metronomskog doziranja kamptotecinskih prolekova (npr. peg-irinotekan) |
| KR20110075029A (ko) * | 2008-10-21 | 2011-07-05 | 엔즌 파마슈티칼스, 인코포레이티드 | 7-에틸-10-하이드록시캄토테신의 다중-암 고분자 컨쥬게이트로 신경모세포종의 치료 |
| GB2469791B (en) * | 2009-04-23 | 2011-12-14 | Londonpharma Ltd | Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease |
| BRPI1014887A8 (pt) * | 2009-04-23 | 2019-02-12 | Londonpharma Ltd | composição farmacêutica para uso no tratamento de neoplasias e uso de um composto provendo di-hidroartemesinina via dosagem sublingual, transmucosal, bucal ou nasal |
| JP5624735B2 (ja) | 2009-07-22 | 2014-11-12 | 国立大学法人岡山大学 | フィルター |
| CN102399142B (zh) * | 2010-09-14 | 2014-09-24 | 华北制药集团新药研究开发有限责任公司 | 一类倍半萜酯化合物及其制备方法和用途 |
| US20130331443A1 (en) | 2010-12-22 | 2013-12-12 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
| US10894087B2 (en) | 2010-12-22 | 2021-01-19 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
| CN102727522B (zh) * | 2011-04-08 | 2013-09-25 | 石雁羽 | 由溴代双氢青蒿素和Fe2+剂组成的复方双释胶囊制剂 |
| CN103845360A (zh) * | 2012-11-29 | 2014-06-11 | 昆明制药集团股份有限公司 | 含蒿甲醚的药物组合物、制剂及其用途 |
| CN103405779B (zh) * | 2013-07-18 | 2015-09-30 | 江苏省血吸虫病防治研究所 | 一种预防血吸虫感染长效青蒿琥酯药物及其制备方法 |
| GB201800736D0 (en) | 2018-01-17 | 2018-02-28 | St Georges Hospital Medical School | Combination therapy for treatment of leukemia |
| CN109908137B (zh) * | 2019-03-11 | 2022-02-18 | 江苏省人民医院（南京医科大学第一附属医院） | 青蒿素在杀伤乳腺癌干细胞的药物中的应用 |
| CN114983999A (zh) * | 2022-06-09 | 2022-09-02 | 四川大学 | 一种青蒿素及其衍生物的新用途、验证方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4916204A (en) * | 1987-07-31 | 1990-04-10 | Massachusetts Institute Of Technology | Pure polyanhydride from dicarboxylic acid and coupling agent |
| FR2630329B1 (fr) * | 1988-04-20 | 1991-07-05 | Merieux Inst | Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications |
| RU2098407C1 (ru) * | 1989-09-27 | 1997-12-10 | Рон-Пуленк Рорер С.А. | Способ получения пероксиацетальлактонового соединения (варианты) и лактон |
| US5681811A (en) * | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5472684A (en) * | 1993-06-02 | 1995-12-05 | Colgate Palmolive Company | Oral compositions for plaque and gingivitis |
| US5578637A (en) * | 1995-05-03 | 1996-11-26 | University Of Washington | Methods of inhibition or killing cancer cells using an endoperoxide |
| US5677468A (en) * | 1995-06-29 | 1997-10-14 | Hauser, Inc. | Artemisinin dimer compounds having anticancer activity |
| US5869310A (en) * | 1996-06-03 | 1999-02-09 | Promega Corporation | Isolated agarase enzyme from flavobacterium sp. strain NR19, cloned genes therefor, and expression thereof in transformed host cells |
| US6160004A (en) * | 1997-12-30 | 2000-12-12 | Hauser, Inc. | C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumor activities |
| CN1084333C (zh) * | 1998-06-17 | 2002-05-08 | 中国科学院上海药物研究所 | 新的青蒿素化合物,其制备方法以及含有它们的药物组合物 |
| US6127405A (en) * | 1998-07-10 | 2000-10-03 | Council Of Scientific And Industrial Research | Method for the use of alpha arteether as an anti-bacterial and anti-fungal agent |
| US6297272B1 (en) * | 1999-01-12 | 2001-10-02 | Hauser, Inc. | Artemisinin analogs having antimalarial antiproliferative and antitumor activities and chemoselective methods of making the same |
| IN191696B (enExample) * | 1999-02-12 | 2003-12-20 | Council Scient Ind Res | |
| GB9916012D0 (en) * | 1999-07-09 | 1999-09-08 | Ufc Limited | Peroxide-based antimalarial compounds |
| JP2002128784A (ja) * | 2000-10-25 | 2002-05-09 | Japan Science & Technology Corp | 細胞侵入型励起一重項酸素発生化合物および該化合物を含む薬剤類 |
| EP1395264A4 (en) * | 2001-05-16 | 2006-03-22 | Faulk Pharmaceuticals Inc | TARGETED RELEASE OF MEDICAMENTS FOR THE TREATMENT OF PARASITIC INFECTIONS |
-
2003
- 2003-06-06 RU RU2004139090/14A patent/RU2004139090A/ru unknown
- 2003-06-06 JP JP2004510709A patent/JP2005529938A/ja active Pending
- 2003-06-06 CN CNA038167972A patent/CN1668293A/zh active Pending
- 2003-06-06 AU AU2003243418A patent/AU2003243418B2/en not_active Ceased
- 2003-06-06 AU AU2003251405A patent/AU2003251405A1/en not_active Abandoned
- 2003-06-06 EP EP03757363A patent/EP1553935A4/en not_active Withdrawn
- 2003-06-06 NZ NZ537114A patent/NZ537114A/en not_active IP Right Cessation
- 2003-06-06 JP JP2004510713A patent/JP4440768B2/ja not_active Expired - Fee Related
- 2003-06-06 NZ NZ537113A patent/NZ537113A/en unknown
- 2003-06-06 CN CNB038167956A patent/CN1313145C/zh not_active Expired - Fee Related
- 2003-06-06 EP EP03757380A patent/EP1531851B1/en not_active Expired - Lifetime
- 2003-06-06 BR BR0311627-1A patent/BR0311627A/pt not_active IP Right Cessation
- 2003-06-06 CA CA002488347A patent/CA2488347A1/en not_active Abandoned
- 2003-06-06 BR BR0312685-4A patent/BR0312685A/pt not_active IP Right Cessation
- 2003-06-06 CA CA002488360A patent/CA2488360A1/en not_active Abandoned
- 2003-06-06 WO PCT/US2003/017791 patent/WO2003103588A2/en not_active Ceased
- 2003-06-06 RU RU2004139096/15A patent/RU2325156C2/ru not_active IP Right Cessation
- 2003-06-06 US US10/457,079 patent/US20040058981A1/en not_active Abandoned
- 2003-06-06 CN CN201010165713A patent/CN101843904A/zh active Pending
-
2005
- 2005-01-03 ZA ZA200500023A patent/ZA200500023B/en unknown
-
2007
- 2007-11-30 US US11/948,560 patent/US20080119542A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR0311627A (pt) | 2005-08-30 |
| AU2003243418A1 (en) | 2003-12-22 |
| EP1531851A2 (en) | 2005-05-25 |
| WO2003103588A3 (en) | 2004-04-15 |
| RU2325156C2 (ru) | 2008-05-27 |
| EP1553935A2 (en) | 2005-07-20 |
| WO2003103588A2 (en) | 2003-12-18 |
| CN1313145C (zh) | 2007-05-02 |
| JP2005535606A (ja) | 2005-11-24 |
| EP1531851A4 (en) | 2007-12-12 |
| AU2003243418B2 (en) | 2009-02-19 |
| EP1531851B1 (en) | 2011-12-14 |
| CA2488347A1 (en) | 2003-12-18 |
| NZ537114A (en) | 2007-02-23 |
| CN101843904A (zh) | 2010-09-29 |
| NZ537113A (en) | 2007-01-26 |
| EP1553935A4 (en) | 2010-07-07 |
| BR0312685A (pt) | 2005-09-06 |
| CN1668323A (zh) | 2005-09-14 |
| US20040058981A1 (en) | 2004-03-25 |
| US20080119542A1 (en) | 2008-05-22 |
| ZA200500023B (en) | 2005-10-20 |
| JP4440768B2 (ja) | 2010-03-24 |
| JP2005529938A (ja) | 2005-10-06 |
| CA2488360A1 (en) | 2003-12-18 |
| CN1668293A (zh) | 2005-09-14 |
| RU2004139096A (ru) | 2005-06-10 |
| AU2003251405A1 (en) | 2003-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004139090A (ru) | Способы применения соединений, подобных артемизинину, для профилактики или задержки возникновения злокачественных опухолей | |
| JP2005529938A5 (enExample) | ||
| AU620937B2 (en) | Treatment of skin diseases with artemisinin and derivatives | |
| EP2488180A2 (en) | Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease | |
| JP6002835B2 (ja) | 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| WO2004045593A3 (en) | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy | |
| RU2002123641A (ru) | С-4 карбонатсодержащие таксаны | |
| KR101100786B1 (ko) | 암에 대한 방사선 치료 증진용 조성물 | |
| KR102664243B1 (ko) | 암 환자의 치료에 유용한 오줌의 알칼리제 | |
| JP4994618B2 (ja) | Ｔｓ−１／カンプトテシン類による化学放射線療法 | |
| WO1996035417A1 (en) | Combinations of anti-oestrogen compounds and pkc modulators and their use in cancer therapy | |
| US20050026852A1 (en) | Method of augmenting the antitumor activity of anticancer agents | |
| Wang et al. | Combination treatment with bortezomib and thiostrepton is effective against tumor formation in mouse models of DEN/PB-induced liver carcinogenesis | |
| US20050043274A1 (en) | Pharmaceutical compositions and methods for lowering blood pressure and pulse rate | |
| TWI598095B (zh) | 治療或緩解高齡或末期癌症患者用之醫藥組合物 | |
| AU2005251588B2 (en) | Antitumor effect fortifier, antitumor agent and method of therapy for cancer | |
| Kim et al. | Indeno [1, 2-c] isoquinolines as enhancing agents on all-trans retinoic acid-mediated differentiation of human myeloid leukemia cells | |
| EP4027996A1 (en) | Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma | |
| JP3815736B2 (ja) | 腫瘍転移抑制剤 | |
| US20080039485A1 (en) | Low-dose-long-term pharmaceutical composition comprising camptothecin derivatives for the treatment of cancers | |
| RU2012114771A (ru) | Фармацевтическая комбинация для лечения опухоли | |
| WO2010031766A1 (en) | Pharmaceutical combination of 1-(2-tetrahydrofuryl)-5-fluorouracil and caffeic acid phenethyl ester for oral treating of tumors | |
| RU2006132741A (ru) | С10 циклопентил сложноэфирные таксаны | |
| RU2021118927A (ru) | Композиции и способы для уменьшения значительных тромботических явлений у пациентов со злокачественной опухолью | |
| Lee et al. | A lipid-soluble ginseng extract inhibits human large cell lung cancer (NCI-H460) cells xenograft in vivo and the proliferation of cancer cells in vitro |